Breaking News Instant updates and real-time market news.

AGN

Allergan

$231.11

-1.255 (-0.54%)

, BMY

Bristol-Myers

$50.39

0.15 (0.30%)

11:55
10/14/16
10/14
11:55
10/14/16
11:55

Piper Jaffray biopharma analyst holds an analyst/industry conference call

Biopharmaceuticals Analyst Schimmer discusses the roles of bile acids and FXR agonists for treatment of Non-Alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) on an Analyst/Industry conference call to be held on October 14 at 1 pm.

AGN

Allergan

$231.11

-1.255 (-0.54%)

BMY

Bristol-Myers

$50.39

0.15 (0.30%)

ENTA

Enanta

$24.64

-0.22 (-0.88%)

GALT

Galectin Therapeutics

$0.86

-0.04 (-4.44%)

GILD

Gilead

$73.06

0.03 (0.04%)

GLMD

Galmed

$3.84

-0.12 (-3.03%)

ICPT

Intercept

$144.10

-0.65 (-0.45%)

MRK

Merck

$62.50

-0.01 (-0.02%)

RGLS

Regulus

$3.08

-0.04 (-1.28%)

TBRA

Tobira Therapeutics

$40.33

0.23 (0.57%)

VKTX

Viking Therapeutics

$1.16

-0.04 (-3.33%)

  • 15

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 11

    Nov

  • 29

    Nov

  • 14

    Dec

AGN Allergan
$231.11

-1.255 (-0.54%)

09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
10/14/16
LEER
10/14/16
NO CHANGE
Target $294
LEER
Outperform
Leerink positive on Allergan ahead of Restasis patent decision
Leerink analyst Jason Gerberry is positive on Allergan's franchise outlook as he believes the company will either maintain a double-digit top-line" growth pharma" trajectory or alternatively institute a dividend, and will prevail in the ongoing Restasis patent challenge. Gerberry likes Allergan's underlying growth trends of the gastro and derm franchises and pipeline optionality, and reiterates an Outperform rating and $294 price target on the shares.
BMY Bristol-Myers
$50.39

0.15 (0.30%)

10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
GSCO
10/13/16
DOWNGRADE
GSCO
Buy
Bristol-Myers downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Jami Rubin removed Bristol-Myers from the Conviction Buy List and lowered its price target to $67 from $75 saying disappointing CM-26 data adds a greater level of uncertainty to future trials. He continues to believe is well positioned for 2017, and view the shares as very attractive over the long-term.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
ENTA Enanta
$24.64

-0.22 (-0.88%)

04/28/16
JMPS
04/28/16
DOWNGRADE
JMPS
Market Perform
Enanta downgraded to Market Perform from Outperform at JMP Securities
10/23/15
10/23/15
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: A. Schulman (SHLM) downgraded to Accumulate from Buy at Seaport Global... American Electric (AEP) downgraded to Neutral from Outperform at Credit Suisse... Applied Materials (AMAT) downgraded to Neutral from Buy at Citi... ArcelorMittal (MT) downgraded to Neutral from Outperform at Credit Suisse... BE Aerospace (BEAV) downgraded to Sector Perform from Outperform at RBC Capital... Banner Corp. (BANR) downgraded to Market Perform from Outperform at Keefe Bruyette... CEMEX (CX) downgraded to Equal Weight from Overweight at Barclays... Cabela's (CAB) downgraded to Market Perform from Outperform at Barrington... Cameron (CAM) downgraded to Market Perform from Outperform at Raymond James... Community Financial (TCFC) downgraded to Market Perform at Keefe Bruyette... Cypress Semiconductor (CY) downgraded to Buy from Strong Buy at Needham... Diana Shipping (DSX) downgraded to Hold from Buy at Jefferies... Dunkin' Brands (DNKN) downgraded to Neutral from Overweight at Piper Jaffray... Emerge Energy (EMES) downgraded to Neutral from Buy at Seaport Global... Enanta (ENTA) downgraded to Underweight from Equal Weight at Barclays... FireEye (FEYE) downgraded to Neutral from Outperform at Wedbush... Freescale (FSL) downgraded ahead of deal closing at Bernstein... GNC Holdings (GNC) downgraded to Neutral from Buy at Sterne Agee CRT... Heritage Financial (HFWA) downgraded to Market Perform at Keefe Bruyette... Huron (HURN) downgraded to Underperform from Outperform at Avondale... Independent Bank (IBTX) downgraded to Hold from Buy at Sandler O'Neill... KLX Inc. (KLXI) downgraded at RBC Capital... LaSalle Hotel (LHO) downgraded to Neutral from Outperform at Credit Suisse... LifePoint (LPNT) downgraded to Buy from Conviction Buy at Goldman... Mead Johnson (MJN) downgraded to Neutral from Outperform at Credit Suisse... Mindray Medical (MR) downgraded to Hold from Buy at Deutsche Bank... NASDAQ (NDAQ) downgraded to Market Perform from Outperform at Wells Fargo... Ocular Therapeutix (OCUL) downgraded to Equal Weight from Overweight at Morgan Stanley... Pandora (P) downgraded to Neutral from Buy at BofA/Merrill... Pebblebrook Hotel (PEB) downgraded to Neutral from Outperform at Credit Suisse... Plexus (PLXS) downgraded to Neutral from Buy at Goldman... Quidel (QDEL) downgraded to Hold from Buy at Craig-Hallum... Quotient Technology (QUOT) downgraded to Hold from Buy at Craig-Hallum... Raytheon (RTN) downgraded to Peer Perform from Outperform at Wolfe Research... Safe Bulkers (SB) downgraded to Hold from Buy at Jefferies... Sanmina (SANM) downgraded to Sell from Neutral at Citi... Skechers (SKX) downgraded to Neutral from Buy at Buckingham... Stericycle (SRCL) downgraded to Neutral from Outperform at Baird... Teck Resources (TCK) downgraded to Sell from Hold at Deutsche Bank... Trinity Biotech (TRIB) downgraded to Hold from Buy at Craig-Hallum... USG (USG) downgraded to Hold from Buy at Jefferies... Ultra Clean (UCTT) downgraded to Hold from Buy at Craig-Hallum... Under Armour (UA) downgraded to Hold from Buy at BB&T... Union Pacific (UNP) downgraded to Underperform at Avondale... Vishay (VSH) downgraded to Sell from Neutral at Citi... WABCO (WBC) downgraded to Buy from Conviction Buy at Goldman.
10/23/15
10/23/15
UPGRADE

On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Apple (AAPL) upgraded to Buy from Hold at Maxim... Cabela's (CAB) upgraded to Neutral from Sell at Goldman... EQT Corporation (EQT) upgraded to Buy from Accumulate at KLR Group... East West Bancorp (EWBC) upgraded to Outperform from Market Perform at Wells Fargo... Enanta (ENTA) upgraded to Outperform from Market Perform at JMP Securities... Equifax (EFX) upgraded on valuation, Veda deal, growth outlook at Stifel... KLA-Tencor (KLAC) upgraded to Neutral from Sell at Citi... Kimberly-Clark (KMB) upgraded to Buy from Hold at Societe Generale... Man Group (MNGPY) upgraded to Buy from Hold at Jefferies... McDonald's (MCD) upgraded to Overweight from Neutral at Piper Jaffray... Microsoft (MSFT) upgraded to Buy from Neutral at BofA/Merrill... Netgear (NTGR) upgraded to Outperform from Underperform at Raymond James... Pacific Biosciences (PACB) upgraded to Overweight from Neutral at Piper Jaffray... Progenics (PGNX) assumed with a Buy from Hold at Jefferies... Stanley Black & Decker (SWK) upgraded to Buy from Outperform at CLSA... Teck Resources (TCK) upgraded to Buy from Hold at BB&T... ZS Pharma (ZSPH) upgraded to Overweight from Equal Weight at Morgan Stanley... athenahealth (ATHN) upgraded to Outperform from Market Perform at Raymond James.
10/23/15
JEFF
10/23/15
NO CHANGE
Target $85
JEFF
Buy
Jefferies 'strongly' advises buying AbbVie on the weakness
Jefferies analyst Jeffrey Holford "strongly' advises investors use yesterday's selloff in shares of AbbVie as a buying opportunity. The FDA warning letter applies to a very limited population within the hepatitis C market, which means it will have a limited impact on AbbVie's HCV franchise, Holford tells investors in a research note. Competitor Gilead (GILD) has also seen excess events in the Child-Pugh B population, the analyst points out. He keeps a Buy rating on AbbVie with an $85 price target. The stock closed yesterday down $5.57 to $48.26. Its partner Enanta Pharmaceuticals (ENTA) dropped $16.35 to $23.90.
GALT Galectin Therapeutics
$0.86

-0.04 (-4.44%)

09/28/16
ROTH
09/28/16
DOWNGRADE
Target $0.75
ROTH
Sell
Galectin Therapeutics downgraded to Sell from Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv downgraded Galectin Therapeutics to Sell from Buy after the company announced that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. The analyst estimates Galectin has approximately $15M, sufficient to last through mid-2017, with the next significant milestone likely in December 2017. Yaniv expects the shares to continue to experience downward pressure over the coming 15 months. He lowered his price target on the stock to 75c from $3.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
HCWC
09/29/16
DOWNGRADE
Target $1.5
HCWC
Neutral
Galectin Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Galectin Therapeutics to Neutral after the company reported that the Phase 2 NASH-FX trial missed its primary endpoint. The analyst cut his price target for the shares to $1.50 from $8. He has "increased doubts about the true therapeutic effect of GR-MD-02 on fibrosis or cirrhosis."
10/03/16
FBRC
10/03/16
DOWNGRADE
Target $2
FBRC
Market Perform
Galectin Therapeutics downgraded to Market Perform from Outperform at FBR Capital
FBR Capital analyst Vernon Bernardino downgraded Galectin Therapeutics to Market Perfrom and lowered its price target to $2 from $12 following the failure of NASH-FX to meet its primary and secondary endpoints. The study was one of two ongoing Phase II clinical trials to evaluate GALTb's galectin-3 inhibitor drug candidate, GRMD-02, in patients with non-alcoholic steatohepatitis.
GILD Gilead
$73.06

0.03 (0.04%)

09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
GLMD Galmed
$3.84

-0.12 (-3.03%)

03/28/16
HCWC
03/28/16
INITIATION
Target $22
HCWC
Buy
Galmed assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce assumed coverage of Galmed Pharmaceuticals with a Buy rating and $22 price target.
07/06/16
ROTH
07/06/16
INITIATION
Target $6
ROTH
Buy
Galmed coverage resumed with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv resumed coverage of Galmed with a Buy rating and $6 price target.
07/06/16
07/06/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with a Buy at Longbow. 2. Galmed (GLMD) coverage resumed with a Buy at Roth Capital. 3. Kite Pharma (KITE) and Juno Therapeutics (JUNO) initiated with an Equal Weight at Barclays. 4. Nautilus (NLS) initiated with an Outperform at Imperial Capital. 5. Royal Gold (RGLD) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ICPT Intercept
$144.10

-0.65 (-0.45%)

07/07/16
CANT
07/07/16
INITIATION
Target $58
CANT
Sell
Cantor starts Intercept witih Sell rating, $58 price target
Cantor Fitzgerald analyst Elemer Piros initiated after the close yesterday shares of Intercept Pharmaceuticals (ICPT) with a Sell rating and $58 price target. The stock closed yesterday down 62c to $142.85. The analyst is "unenthusiastic" about Ocaliva's future in nonalcoholic steatohepatitis. He identified six areas of weaknesses in the previous clinical package and the design of the currently ongoing Phase III trial. Piros last night also initiated shares of Tobira Therapeutics (TBRA) with a Buy rating and $27 price target. The company could become a leading contender for the treatment of nonalcoholic steatohepatitis following its data release in Q3, the analyst told investors in a research note.
07/25/16
RBCM
07/25/16
NO CHANGE
RBCM
Intercept mentioned positively at RBC Capital
09/20/16
BARD
09/20/16
NO CHANGE
BARD
Outperform
Intercept shares remain undervalued, says Baird
09/21/16
BARD
09/21/16
NO CHANGE
Target $332
BARD
Outperform
Intercept undervalued based on Allergan's upfront payment for Tobira, says Baird
Baird analyst Brian Skorney is positive on the yesterday's merger activity in the NASH space, specifically Allergan's (AGN) offer to buy Tobira Therapeutics (TBRA). Based on the upfront payment to Tobira from Allergan, Skorney said he can't help but question whether Intercept (ICPT) shares are undervalued. Skorney reiterated his Outperform rating on Intercept shares and keeps a $332 price target on the stock.
MRK Merck
$62.50

-0.01 (-0.02%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
BOFA
10/13/16
UPGRADE
Target $70
BOFA
Buy
Merck upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Colin Bristow upgraded Merck to Buy and raised its price target to $70 from $57 to reflect its opportunity in first line lung cancer. Bristow significantly raised his Keytruda sales estmate to 7.5B from $5.5B following Merck's first line lung cancer data presentations at ESMO over the weekend and feedback from experts. He expects Keytruda to receive early approval/launch in first line NSCLC from the December 24 PDUFA and to become the standard of care in the identified label and further upside from chemo combo.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
RGLS Regulus
$3.08

-0.04 (-1.28%)

07/28/16
WELS
07/28/16
NO CHANGE
WELS
Regulus price target lowered to $6.75-$8 from $16-$21 at Wells Fargo
Wells Fargo cut its price target on Regulus after the FDA requested detailed safety data about the company's HCV drug, RG-101, as well as information regarding the drug's potential impact on hepatoxicity and a risk/benefit assessment for the proposed therapeutic regimens containing RG-101. Wells thinks that there is some risk that the "FDA may not see the benefit of a 4-week or shorter course of HCV treatment." However, the firm says that the stock's risk/reward ratio remains positive, and it keeps an Outperform rating.
06/28/16
BMOC
06/28/16
DOWNGRADE
BMOC
Market Perform
Regulus downgraded on FDA hold at BMO Capital
As noted earlier, BMO Capital downgraded Regulus to Market Perform from Outperform. The firm downgraded the stock after the FDA placed a hold on the company's lead drug, RG-101. The firm thinks that the hold raises questions about the drug's safety. Target to $4 from $16.
06/28/16
COWN
06/28/16
NO CHANGE
COWN
Outperform
Regulus remains attractive on pipeline opportunities, says Cowen
Cowen noted the FDA has placed Regulus's RG-101 program on hold after a second case of severe jaundice. The firm believes the shares remain attractive based on the company's other pipeline and platform opportunities and maintained its Outperform rating on Regulus shares, which are down over 52% in pre-market trading.
06/28/16
BMOC
06/28/16
DOWNGRADE
BMOC
Market Perform
Regulus downgraded to Market Perform from Outperform at BMO Capital
TBRA Tobira Therapeutics
$40.33

0.23 (0.57%)

09/20/16
STFL
09/20/16
NO CHANGE
Target $6
STFL
Buy
Stifel says Conatus emricasan an interesting asset amid increased focus on NASH
Following Allergan's (AGN) acquisition of small-cap NASH play Tobira (TBRA), Stifel analyst Stephen Willey notes there are some "interesting" similarities between Conatus (CNAT) and the latter. However, the analyst points out that the clearest distinctions between the two are Conatus' emphasis on some of the downstream consequences of NASH fibrosis and the amount of meaningful clinical data generated to date. Willey still thinks Conatus' emricasan is an interesting asset, but urges investors seeking Tobira-like premiums to exercise a level of caution. He reiterates a Buy rating and $6 price target on Conatus' shares. In afternoon trading, shares of Conatus have gained about 20% to $2.10.
09/21/16
CANT
09/21/16
DOWNGRADE
CANT
Hold
Tobira Therapeutics downgraded to Hold from Buy at Cantor
Cantor analyst Elemer Piros downgraded Tobira (TBRA) after the company agreed to be acquired by Allergan (AGN). Target to $42 from $19.
VKTX Viking Therapeutics
$1.16

-0.04 (-3.33%)

04/07/16
HCWC
04/07/16
INITIATION
Target $6
HCWC
Buy
Viking Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther started Viking Therapeutics with a Buy rating and $6 price target.
05/24/16
MAXM
05/24/16
INITIATION
Target $5
MAXM
Buy
Viking Therapeutics initiated with a Buy at Maxim
Target $5.

TODAY'S FREE FLY STORIES

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

17:04
12/02/16
12/02
17:04
12/02/16
17:04
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIR

Osiris

$5.68

0.06 (1.07%)

17:02
12/02/16
12/02
17:02
12/02/16
17:02
Hot Stocks
Osiris: Nasdaq grants company's request for additional time »

Osiris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOR

STORE Capital

$24.45

0.52 (2.17%)

17:00
12/02/16
12/02
17:00
12/02/16
17:00
Hot Stocks
STORE Capital director Donovan acquires 4,350 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARB

Carbonite

$17.95

0.25 (1.41%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
Breaking Hot Stocks news story on Carbonite »

Crosslink lowers stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIB

CGI Group

$47.11

0.16 (0.34%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
CGI Group announces specific share repurchase program »

CGI Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.